Shares of Insmed Incorporated (NASDAQ:INSM) have been assigned an average rating of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $38.29.

A number of analysts have recently issued reports on INSM shares. ValuEngine raised Insmed from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 30th. Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a research note on Saturday, March 2nd. Goldman Sachs Group raised Insmed from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $29.00 to $35.00 in a research note on Thursday, January 17th. BidaskClub raised Insmed from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Finally, JMP Securities raised Insmed from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a research note on Friday, February 15th.

In other Insmed news, Director Donald J. Hayden, Jr. sold 14,900 shares of the business’s stock in a transaction on Friday, February 22nd. The stock was sold at an average price of $28.08, for a total transaction of $418,392.00. Following the transaction, the director now owns 77,097 shares of the company’s stock, valued at $2,164,883.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alfred Altomari sold 5,500 shares of the business’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $30.00, for a total value of $165,000.00. Following the transaction, the director now directly owns 25,942 shares in the company, valued at approximately $778,260. The disclosure for this sale can be found here. Insiders have sold 32,186 shares of company stock worth $942,017 in the last three months. 4.95% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP purchased a new position in shares of Insmed during the 3rd quarter worth approximately $4,396,000. JPMorgan Chase & Co. lifted its holdings in Insmed by 91.5% in the third quarter. JPMorgan Chase & Co. now owns 506,391 shares of the biopharmaceutical company’s stock valued at $10,240,000 after buying an additional 241,921 shares during the period. AQR Capital Management LLC lifted its holdings in Insmed by 4.4% in the third quarter. AQR Capital Management LLC now owns 103,376 shares of the biopharmaceutical company’s stock valued at $2,090,000 after buying an additional 4,373 shares during the period. Teachers Advisors LLC lifted its holdings in Insmed by 9.3% in the third quarter. Teachers Advisors LLC now owns 292,278 shares of the biopharmaceutical company’s stock valued at $5,910,000 after buying an additional 24,973 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Insmed by 2.3% in the third quarter. Vanguard Group Inc. now owns 6,802,706 shares of the biopharmaceutical company’s stock valued at $137,551,000 after buying an additional 154,130 shares during the period.

Shares of NASDAQ:INSM traded up $0.72 during trading on Monday, reaching $29.28. The stock had a trading volume of 622,769 shares, compared to its average volume of 903,795. The company has a debt-to-equity ratio of 2.48, a current ratio of 4.82 and a quick ratio of 4.69. The firm has a market capitalization of $2.31 billion, a PE ratio of -7.02 and a beta of 2.98. Insmed has a 1-year low of $11.31 and a 1-year high of $33.13.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by ($0.02). The firm had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $19.61 million. As a group, analysts expect that Insmed will post -3.57 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Recommended Story: How is inflation measured?

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.